BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20250731T034755EDT-8068m1fEjj@132.216.98.100
DTSTAMP:20250731T074755Z
DESCRIPTION:Zoom link: https://mcgill.zoom.us/j/83520438960\n\nAbstract:\n
 \nAdvances in DNA sequencing have radically accelerated our understanding 
 of the genetic basis of human disease. However\, many of human genes encod
 e proteins that remain uncharacterized and lack selective small-molecule p
 robes. The functional annotation of these proteins should enrich our knowl
 edge of the biochemical pathways that support human physiology and disease
 \, as well as lead to the discovery of new therapeutic targets. To address
  these problems\, we have introduced chemical proteomic technologies that 
 globally profile the functional state of proteins in native biological sys
 tems. Prominent among these methods is activity-based protein profiling (A
 BPP)\, which utilizes chemical probes to map the activity state of large n
 umbers of proteins in parallel. In this lecture\, I will describe the appl
 ication of ABPP to discover and functionally annotate proteins that contri
 bute to human diseases\, such as cancer and autoimmunity. I will also disc
 uss the generation and implementation of advanced ABPP platforms for prote
 ome-wide ligand discovery and how the integration of these global ‘liganda
 bility’ maps with emergent human genetic information and phenotypic screen
 ing can expand the druggable fraction of the human proteome for basic and 
 translational research objectives.\n\nBio:\n\nDr. Cravatt is a Professor a
 nd the Norton B. Gilula Chair of Chemical Biology in the Department of Che
 mistry at The Scripps Research Institute. His research group is interested
  in developing chemical proteomic technologies that enable protein and dru
 g discovery on a global scale and applying these methods to characterize b
 iochemical pathways that play important roles in human physiology and dise
 ase\, especially as pertains to the nervous system and cancer. Dr. Cravatt
  obtained his undergraduate education at Stanford University\, receiving a
  B.S. in the Biological Sciences and a B.A. in History. He then received a
  Ph.D. from The Scripps Research Institute (TSRI) in 1996. Professor Crava
 tt joined the faculty at TSRI in 1997. Dr. Cravatt is an Associate Editor 
 for JACS and is a co-founder of Activx Biosciences\, Abide Therapeutics\, 
 and Vividion Therapeutics. His honors include a Searle Scholar Award\, the
  Eli Lilly Award in Biological Chemistry\, a Cope Scholar Award\, the ASBM
 B Merck Award\, the RSC Jeremy Knowles Award\, the AACR Award for Achievem
 ent in Chemistry in Cancer Research\, and memberships in the American Acad
 emy of Arts and Sciences\, National Academy of Medicine\, and National Aca
 demy of Sciences.\n
DTSTART:20201117T180000Z
DTEND:20201117T193000Z
SUMMARY:The 2019 Bernard Belleau Lecture: Ben Cravatt - Activity-based prot
 eomics – target and ligand discovery on a global scale
URL:/chemistry/channels/event/2019-bernard-belleau-lec
 ture-ben-cravatt-activity-based-proteomics-target-and-ligand-discovery-320
 797
END:VEVENT
END:VCALENDAR